– USA, CA – Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Jessica Grossman, M.D., to its board of directors. Dr. Grossman is currently the CEO of Medicines360, a global nonprofit women’s health pharmaceutical company that developed the FDA-approved contraceptive IUS LILETTA (levonorgestrel-releasing intrauterine system).
“We are excited to add Dr. Grossman to our highly distinguished board of directors,” said Sabrina Martucci Johnson, CEO of Daré Bioscience. “Dr. Grossman brings a deep understanding of women’s health along with relevant experience in product development, partnering and commercialization.”
Prior to her appointment as CEO of Medicines360, Dr. Grossman served as President and Founding CEO of Sense4Baby, Inc., which developed an innovative, wireless maternal fetal heart rate monitoring system for women with high-risk pregnancies. Dr. Grossman was also Founder and President of Gynesonics, Inc., an early-stage medical device company focused on minimally invasive solutions for women’s health, which developed the first intrauterine, ultrasound-guided radiofrequency ablation device for fibroid tumors.
“I am pleased to join the Daré board of directors,” said Dr. Grossman. “I believe that Daré is at the leading edge of innovation, and I’m looking forward to helping the company deliver on its mission and vision to identify and address unmet needs in women’s sexual and reproductive health.”
Dr. Grossman earned a Medical Degree from Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia and an undergraduate degree with honors from Brandeis University. In addition to her academic and professional accreditations, she has also performed research at the Beth Israel Deaconess Medical Center, part of the Harvard Medical School system.
Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical company with a mission to expand access to quality medicines for all women regardless of their socioeconomic status, insurance coverage or geographic location. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health that address clear therapeutic gaps. The company is driven by a mission to identify, develop and bring to market a diverse portfolio of novel and differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Daré currently has two product candidates in clinical development. The first is Ovaprene, a non-hormonal monthly contraceptive ring intended to provide protection over multiple weeks between menses. The second is SST-6007 (5% Topical Sildenafil Citrate Cream), a potential treatment for Female Sexual Arousal Disorder. SST-6007 incorporates sildenafil, the same active ingredient in Viagra, in a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience. Daré also has an option to enter into a license agreement for ORB-204 and ORB-214, preclinical stage injectable etonogestrel contraceptives with target 6- and 12-month durations.
For more information : http://www.darebioscience.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.